US2018155784A1PendingUtilityA1
Cetp inhibitors for therapeutic use
Est. expiryMar 27, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 9/10A61P 43/00A61P 7/00A61P 9/00A61P 3/06A61P 3/10A61P 3/04A61K 31/167C12Q 1/6874C12Q 1/6827C12Q 2600/106C12Q 1/686C12Q 2600/158
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
Claims
exact text as granted — not AI-modified1 - 61 . (canceled)
62 . A method for treating a cardiovascular disorder, comprising administering an effective amount of torcetrapib, anacetrapib, evacetrapib, BAY 60-5521, DEZ-001, ATH-03, DRL-17822 or DLBS-1449 to a subject in need thereof and known to carry one or more of the following improved response genotypes: rs1967309/AA, rs1967309/AG, rs12595857/GG, rs12595857/AG, rs111590482/AG, rs111590482/GG, rs11647828/AG, rs12935810/GG, rs17136707/GG, rs17136707/AG, rs2239310/GG, rs2239310/AG, rs2283497/AA, rs2283497/CA, rs2531967/AA, rs2531967/GA, rs3730119/AA, rs3730119/GA, rs4786454/AA, rs4786454/GA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8049452/GA, rs8061182/AA, rs8061182/AG, rs11647828/GG, and rs13337675/AG.
63 . The method of claim 62 , wherein the one or more improved response genotypes are: rs1967309/AA, rs12595857/GG, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, and rs8061182/AA.
64 . The method of claim 62 , wherein the one or more improved response genotypes is rs1967309/AA.
65 . The method of claim 62 , wherein the effective amount is approximately 100 mg to about 1800 mg per day.
66 . The method of claim 62 , wherein the effective amount is about 300 mg to about 900 mg per day.
67 . The method of claim 62 , wherein the effective amount is about 600 mg per day.
68 . A method for reducing the risk of a cardiovascular event, comprising administering an effective amount of torcetrapib, anacetrapib, evacetrapib, BAY 60-5521, DEZ-001, ATH-03, DRL-17822 or DLBS-1449 to a subject in need thereof and known to carry one or more of the following improved response genotypes: rs1967309/AA, rs1967309/AG, rs12595857/GG, rs12595857/AG, rs111590482/AG, rs111590482/GG, rs11647828/AG, rs12935810/GG, rs17136707/GG, rs17136707/AG, rs2239310/GG, rs2239310/AG, rs2283497/AA, rs2283497/CA, rs2531967/AA, rs2531967/GA, rs3730119/AA, rs3730119/GA, rs4786454/AA, rs4786454/GA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8049452/GA, rs8061182/AA, rs8061182/AG, rs11647828/GG, and rs13337675/AG.
69 . The method of claim 68 , wherein the one or more improved response genotypes are: rs1967309/AA, rs12595857/GG, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, and rs8061182/AA.
70 . The method of claim 68 , wherein the one or more improved response genotypes is rs1967309/AA.
71 . The method of claim 68 , wherein the effective amount is approximately 100 mg to about 1800 mg per day.
72 . The method of claim 68 , wherein the effective amount is about 300 mg to about 900 mg per day.
73 . The method of claim 68 , wherein the effective amount is about 600 mg per day.Join the waitlist — get patent alerts
Track US2018155784A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.